Abivax (ABVX) Current Assets (2021 - 2026)
Abivax (ABVX) posted quarterly Current Assets of $600.9 million for Q1 2026, up 330.56% year-over-year from $139.6 million in Q1 2025, and down 6.36% quarter-over-quarter from $641.7 million in Q4 2025.
Abivax (ABVX) Current Assets (2021 - 2026) Analysis & Trends
Abivax's Current Assets history runs 6 years deep, the most recent figure standing at $600.9 million for Q1 2026.
- In Q1 2026, Current Assets rose 330.56% year-over-year to $600.9 million; the TTM figure through Mar 2026 stood at $600.9 million (up 330.56% YoY), while the FY2025 annual figure was $641.7 million, up 251.84% from the prior year.
- Current Assets for Q1 2026 stood at $600.9 million, down from $641.7 million in the prior quarter.
- The five-year high for Current Assets was $724.0 million in Q3 2025, with the low at $36.9 million in Q4 2022.
- The 5-year median for Current Assets is $261.7 million (2024), against an average of $332.5 million.
- The sharpest annual moves came in 2023 and 2025: Current Assets soared 733.54% in 2023, then plunged 62.75% in 2025.
- Abivax's Current Assets stood at $36.9 million in 2022, then jumped by 733.54% to $307.7 million in 2023, then sank by 40.73% to $182.4 million in 2024, then jumped by 251.84% to $641.7 million in 2025, then slipped by 6.36% to $600.9 million in 2026.
- Business Quant data shows ABVX's Current Assets at $600.9 million in Q1 2026, $641.7 million in Q4 2025, and $724.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | 600.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 600.85 Mn |
| Dec 31, 2025 | 641.67 Mn |
| Sep 30, 2025 | 723.99 Mn |
| Jun 30, 2025 | 97.46 Mn |
| Mar 31, 2025 | 139.55 Mn |
| Dec 31, 2024 | 182.38 Mn |
| Jun 30, 2024 | 261.67 Mn |
| Dec 31, 2023 | 307.69 Mn |
| Dec 31, 2022 | 36.91 Mn |
| Dec 31, 2021 | 86.35 Mn |